Related Experiment Video
Updated: Jun 23, 2026
10:52
Correlative Light and Electron Microscopy to Study Microglial Interactions with β-Amyloid Plaques
Published on: June 1, 2016
Methylene blue and Alzheimer's disease
Murat Oz1, Dietrich E Lorke, George A Petroianu
1Integrative Neuroscience Section, Intramural Research Program, National Institute on Drug Abuse, NIH, DHHS, Baltimore, MD 21224, USA. moz@intra.nida.nih.gov
Biochemical Pharmacology
|May 13, 2009
Summary
Methylene blue (MB) shows promise for Alzheimer's disease (AD) by slowing progression. This compound impacts amyloid plaques, mitochondrial function, and neurotransmitter systems, offering potential therapeutic benefits for AD.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline.
- Current treatments for AD offer limited efficacy, necessitating novel therapeutic strategies.
- Methylene blue (MB) is emerging as a potential therapeutic agent for AD due to its multifaceted cellular actions.
Purpose of the Study:
- To review the diverse cellular and molecular actions of methylene blue (MB).
- To evaluate the relevance of MB's effects on neurotransmitter systems and cellular targets in the context of Alzheimer's disease (AD) pathogenesis.
- To summarize the potential of MB-based treatments for Alzheimer's disease.
Main Methods:
- Literature review of studies investigating methylene blue (MB) and its effects on cellular and molecular pathways relevant to Alzheimer's disease (AD).
- Analysis of MB's impact on amyloid plaque formation, neurofibrillary tangles, mitochondrial function, and cellular metabolism.
- Examination of MB's influence on cholinergic, serotonergic, and glutamatergic neurotransmitter systems.
Main Results:
- Methylene blue (MB) has demonstrated the ability to attenuate amyloid plaque and neurofibrillary tangle formation.
- MB partially restores mitochondrial function and improves cellular metabolism, crucial for neuronal health in Alzheimer's disease (AD).
- MB influences key neurotransmitter systems implicated in the pathogenesis of AD and cognitive disorders.
Conclusions:
- The combined effects of methylene blue (MB) on multiple cellular and molecular targets suggest significant potential for treating Alzheimer's disease (AD).
- MB's influence on neurotransmitter systems and its neuroprotective properties warrant further investigation for novel AD therapeutic development.
- MB represents a promising candidate for developing innovative treatment modalities for Alzheimer's disease (AD).
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...